Category: Endologix Inc.Syndicate content

Endologix's Nellix stent graft passes early safety bar

May 28, 2015 by Fink Densford

Endologix says its Nellix stent graft for treating abdominal aortic aneurysms met its primary safety endpoint.

Endologix's Nellix passes early safety bar but reports endoleak issues

Endologix wins IDE approval for aneurysm sealing system

January 3, 2014 by Chris Walker

Endologix launches a clinical trial after landing FDA Investigational Device Exemption for the Nellix endovascular aneurysm sealing system.

Endologix wins IDE approval for aneurysm sealing system

Endologix (NSDQ:ELGX) said it won FDA Investigational Device Exemption for its Nellix endovascular aneurysm sealing system, paving the way for a U.S. clinical trial.

Endologix offers $75M in convertible notes

December 5, 2013 by Chris Walker

Endologix is seeking to raise $75 million through sales of convertible notes with 2018 due dates.

Endologix offering $75 million in convertible notes

Endologix (NSDQ:ELGX) announced this week that the company is offering $75 million in convertible notes.

Cambridge Heart chairman, ex-CEO both resign | Personnel Moves

December 3, 2013 by Chris Walker

Ali Haghighi-Mood, the former president & CEO of Cambridge Heart, and chairman Roderick de Greef both resign for unnamed reasons.


Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.

Endologix posts Q3 sales surge but losses widen

November 6, 2013 by Chris Walker

Third-quarter sales surge for Endologix, but losses widen as it raises its earnings outlook and narrows its sales guidance for the rest of the year.

Endologix 3rd quarter results

Endologix (NSDQ:ELGX) posted sales growth of nearly 25% during the 3rd quarter, but losses widened by nearly 58%.

Irvine, Calif.-based Endologix posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That's a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.

Endologix shares gain 5 points in days following Q2 report

August 6, 2013 by Sony Salzman

Endologix beats the Street as the company's bottom line swings to the black during the 2nd quarter.

Endologix logo

Endologix (NSDQ:ELGX) beat Wall Street estimates by 2 cents and cut losses in the 2nd quarter, sending share prices up 5.3% to almost $16 in the days following the earnings results.